The latest articles, editorials and news releases from InvestorBrandNetwork (IBN), a growing Investor Brand Platform.
RSS Feed for InvestorBrandNetwork (IBN)September 5, 2024 — D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the world’s first commercial supplier of quantum computers, will participate in this month’s Quantum World Congress.
September 4, 2024 — Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc. , is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”).
September 4, 2024 — The extended product roadmap is part of the company’s efforts to strengthen the connection between quantum optimization, AI and Machine Learning (“ML”), in order to bring new Quantum Artificial Intelligence (“AI”) solutions to market D-Wave’s annealing quantum computing solutions could play a key role in improving AI/ML with more efficient model training, reduced energy consumption, and faster time-to-solution The company’s Quantum AI solutions could be transformative, bringing a powerful new set of new computing tools for generative AI D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and the first commercial provider of quantum computers, was featured in a NetworkNewsAudio syndicated broadcast highlighting the company’s extended quantum AI product roadmap and enhancements to its Leap(TM) quantum cloud service. The audio broadcast can be heard at: https://ibn.
September 3, 2024 — Clene (NASDAQ: CLNN), a biopharmaceutical company, is at the forefront of transforming the treatment of neurodegenerative disorders like amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). “Clene’s lead agent, CNM-Au8, targets the nicotinamide adenine dinucleotide (‘NAD+’) pathway to restore and protect neurological function.
August 30, 2024 — Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is announcing that its subsidiary, Bollinger Motors, has added TEC Equipment, Inc. to its sales and service network.
August 29, 2024 — Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, was recently featured on The BioMedWire Podcast, highlighting the important results of CNM-Au8 trials for both amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), and plans for the future (https://ibn.fm/6OOO1). During the podcast, CEO […]
August 28, 2024 — McEwen Mining (NYSE: MUX) (TSX: MUX), a gold and silver producer with operations in Nevada, Canada, Mexico and Argentina, has reached an agreement with YPF Energía Eléctrica S.A. (YPF Luz). The agreement is for YPF Luz to power McEwen Copper Inc.’s large Los Azules copper project with renewable energy. According to the announcement, the agreement […]
August 27, 2024 — Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released findings from its applied research program that sought to evaluate the mode of action facets of its patented DehydraTECH(TM) technology and the glucagon-like peptide 1 (“GLP-1”) drug, semaglutide. The program was conducted in conjunction with the National Research Council of Canada (“NRC”), […]This press release is distributed by InvestorBrandNetwork (IBN).
August 27, 2024 — Electronic monitoring (“EM”) technology innovator SuperCom (NASDAQ: SPCB) is celebrating impressive developments in 2024, reporting “substantial improvements” in its gross profit, operating income, and net income as it secures new orders and contracts from government and judicial system clients. SuperCom’s technology development and deployment are strategically focused on providing EM tools for tracking offenders supervised by nations’ […]This press release is distributed by InvestorBrandNetwork (IBN).
August 27, 2024 — SenesTech (NASDAQ: SNES), the rodent fertility control experts and inventors of the only EPA-registered contraceptive for male and female rats, has closed on an exercise of certain existing warrants. The exercise consisted of purchasing 505,502 shares of the company’s common stock at a reduced exercise price of $4.
August 27, 2024 — Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), offered key business updates and announced financial results for the second quarter ended June 30, 2024. The company reported productive recent months, with encouraging data on lead compound buntanetap’s performance […]This press release is distributed by InvestorBrandNetwork (IBN).
August 27, 2024 — InMed Pharmaceuticals (NASDAQ: INM), a biopharmaceutical company focused on developing proprietary small molecule drug candidates for diseases with high unmet needs, has announced promising outcomes from a long-term preclinical study of its Alzheimer’s Disease (“AD”) drug candidate, INM-901. These new findings confirm and expand upon results from a previous short-term pilot study (https://ibn.
August 27, 2024 — Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced a contract worth approximately $210 million. According to the announcement, Volt Mobility, a leading United Arab Emirates (“UAE”)-based commercial leasing company, has entered into a purchase agreement to acquire 3,000 Class 1 and Class 3 EV cargo vans and trucks over a 16-month […]This press release is distributed by InvestorBrandNetwork (IBN).
August 27, 2024 — Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced a contract worth approximately $210 million. According to the announcement, Volt Mobility, a leading United Arab Emirates (“UAE”)-based commercial leasing company, has entered into a purchase agreement to acquire 3,000 Class 1 and Class 3 EV cargo vans and trucks over a 16-month […]
August 26, 2024 — SenesTech (NASDAQ: SNES), the inventor of ContraPest(R), the only U.S. EPA-registered contraceptive for male and female rats, as well as Evolve(R) and Evolve Mouse(R), EPA-designated minimum risk contraceptives for rodents, recently reported financial results for its second quarter of fiscal 2024, ended June 30, 2024. In addition, Joel Fruendt, President and CEO of SenesTech, and […]
August 26, 2024 — Platinum Group Metals Ltd. (NYSE American: PLG) (TSX: PTM) is the operator of the Waterberg Project, a bulk underground platinum group metals (“PGM”) deposit discovered by Platinum Group in 2011 and located on the Northern Limb of the Bushveld Complex in South Africa. “The Waterberg Project is planned as a fully mechanized platinum, palladium, rhodium […]
August 26, 2024 — McEwen Mining (NYSE: MUX) (TSX: MUX), a gold and silver producer with operations in Nevada, Canada, Mexico and Argentina, has been and will be featured in several events held in August ad September. According to the announcement, McEwen Mining CEO and chief owner Rob McEwen participated in a panel discussion at a recent Fastmarkets webinar; […]
August 26, 2024 — McEwen Mining (NYSE: MUX) (TSX: MUX), a gold and silver producer with operations in Nevada, Canada, Mexico and Argentina, has been and will be featured in several events held in August ad September. According to the announcement, McEwen Mining CEO and chief owner Rob McEwen participated in a panel discussion at a recent Fastmarkets webinar; […]
August 23, 2024 — CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be spotlighted in this month’s Virtual Investor CEO Connect. According to the announcement CNS Pharmaceuticals CEO John Climaco will participate in a live moderated webcast to begin at […]
August 23, 2024 — SenesTech’s (NASDAQ: SNES) flagship product, Evolve(TM), has repeatedly demonstrated an effective rat control alternative to current market offerings. “The active ingredient in the product has been scientifically proven to reduce rodent fertility, ultimately offering a more proactive approach to addressing the growing rat problem, as opposed to a more reactive approach, as is the case […]